Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUROSTEM Follow-up in Alzheimer's Disease
NCT03172117Phase 2Completed
- Sponsor
- MEDIPOST
- Start
- May 2017
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 2 trial in Alzheimer's disease (AD), sponsored by MEDIPOST. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 24 months. Started May 2017; status: completed.
02
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03172117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172117.